Published in final edited form as:

Curr Immunol Rev. 2009 May 4; 5(4): 267–276. doi:10.2174/157339509789504005.

The Biology of Persistent Infection: Inflammation and Demyelination following Murine Coronavirus Infection of the Central Nervous System

Martin P. Hosking^{1,*} and Thomas E. Lane^{1,2,3,*}

¹ Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697-3900 USA

² Center for Immunology, University of California, Irvine, CA 92697-3900 USA

³ Sue and Bill Gross Stem Cell Center, University of California, Irvine, CA 92697-3900 USA

Abstract

Multiple Sclerosis (MS) is an immune-mediated demyelinating disease of humans. Although causes of MS are enigmatic, underlying elements contributing to disease development include both genetic and environmental factors. Recent epidemiological evidence has pointed to viral infection as a trigger to initiating white matter damage in humans. Mouse hepatitis virus (MHV) is a positive strand RNA virus that, following intracranial infection of susceptible mice, induces an acute encephalomyelitis that later resolves into a chronic fulminating demyelinating disease. Immune cell infiltration into the central nervous system is critical both to quell viral replication and instigate demyelination. Recent efforts by our laboratory and others have focused upon strategies capable of enhancing remyelination in response to viral-induced demyelination, both by dampening chronic inflammation and by surgical engraftment of remyelination – competent neural precursor cells.

I. INTRODUCTION

The most common human demyelinating disease is multiple sclerosis (MS) [1,2], affecting approximately 226,000 individuals in the United States alone [2]. Women are more than twice as likely as men to develop MS [3], and the mean age of disease onset is at approximately 30 years old [2]. MS is a heterogeneous disease, both in presentation and pathology [4,5], and is broadly characterized by immune – mediated demyelination [6,7]. Although the exact causes for MS are as of yet unidentified, and are likely due to numerous genetic and environmental factors [8–11], recent studies have implicated viral infection as either a trigger or cause. It has been reported that clinical symptoms of MS are often preceded by viral infection [12,13]. For example, Epstein Barr virus has been implicated as potential disease agent [8], and infectious mononucleosis significantly raises the risk of later developing MS [14], while varicella-zoster virus particles have also been identified in the cerebral spinal fluid of relapsing MS patients [15]. Other human demyelinating diseases with known or suspected viral etiologies include progressive multifocal leukoencephalopathy [16,17], subacute sclerosing panencephalitis [18], and Guillain-Barre syndrome [19].

With the suspected and confirmed viral etiologies of human demyelinating diseases in mind, researchers have sought to dissect the disparate underlying mechanisms that contribute to

*Address correspondence to: Thomas E. Lane, Department of Molecular Biology & Biochemistry, 3205 McLaugh Hall, University of California, Irvine, Irvine, CA 92697-3900, TEL: (949) 824-5878, FAX: (949) 824-8551, tlane@uci.edu.

pathology and explore endogenous and exogenous mechanisms that influence resolution and repair. Many excellent models exist for the characterization of viral – induced neurologic disease including Theiler's murine encephalitis virus, Semliki Forest Virus, Borna disease virus, and mouse hepatitis virus. This review will focus specifically on mouse hepatitis virus (MHV) as a model system for understanding and treating viral – induced encephalomyelitis and demyelination.

II. MOUSE HEPATITIS VIRUS: AN OVERVIEW

MHV is a positive – strand RNA virus and a member of the family *Coronaviridae*, representing a significant ubiquitous group of viral pathogens that infect both humans and animals, causing respiratory, gastro-intestinal, and neurologic diseases. Coronaviruses are enveloped and possess, to date, the largest described RNA viral genome (27–31 kb) [20,21] MHV, a group II coronavirus, is a natural pathogen of mice, normally infecting the liver, gastrointestinal tract, and central nervous system (CNS), causing a wide range of disease, including hepatitis, gastroenteritis, and acute and chronic encephalomyelitis [20–22]. MHV pathogenesis is dependent upon several factors including viral strain, mouse background, and inoculation route [23]. Structurally, MHV is comprised of three main proteins: the nucleocapsid (N, 60 kDa) which forms a helical complex with the genome, the membrane protein (M, 25 kDa) which associates with the nucleocapsid and aids in envelope formation and budding, and the extracellular spike glycoprotein (S, 180 kDa) which associates with the membrane protein and controls host cell receptor recognition and fusion [20,21,23]. MHV spike glycoprotein recognizes the host cell receptor carcinoembryonic antigen-cell adhesion molecule (CEACAM-1) [24,25] and dictates host pathogenesis [26–28]. Mice lacking CEACAM-1 are refractory to MHV infection [29], however productive infections independent of CEACAM-1 have been observed *in vitro* [30,31] and *in vivo* [32], indicating that alternate receptors and/or mechanisms for MHV infection may exist. Indeed, a pregnancy – specific glycoprotein related to the CEACAM family can function as a receptor for some strains of MHV *in vitro* [33]. MHV may also be capable of infecting CEACAM-1 negative cells through cell – to – cell contact mediated through spike glycoprotein and syncytia formation [26,30,34]. Within the CNS, CEACAM-1 expression is low, especially when compared to endothelial and epithelial cells of the respiratory and digestive systems and hepatocytes [35]. In fact, CEACAM-1 expression has, to date, only been described on CNS endothelial cells [36] and microglia [37]. *In vivo*, MHV infects and replicates within CEACAM-1⁺ (microglia and endothelia) and CEACAM-1[−] (oligodendroglia and astroglia) cells of the CNS [38], indicating that both CEACAM-1 dependent and independent mechanisms of infection are likely responsible for MHV spread during CNS infection.

Intracranial inoculation of susceptible strains of mice with neuroadapted strains of MHV induces an acute encephalomyelitis that eventually evolves into a chronic fulminating demyelinating disease [39]. During acute encephalomyelitis, MHV infection stimulates the production of pro-inflammatory cytokines and chemokines that activate and attract the anti-viral arms of the immune system [40–42]. The generation of anti-viral effector T lymphocytes is absolutely required for controlling viral replication via IFN- γ secretion or cytolytic activity [43,44]. Eventually MHV is cleared below detectable levels; however sterile immunity is not achieved. The majority of mice that survive the initial acute encephalomyelitis develop immune-mediated chronic demyelinating disease, characterized by viral persistence within white matter tracts of the spinal cord and continued infiltration of T lymphocytes and macrophages [45–48]. Based upon the histological and pathological similarities to MS, MHV infection of mice offers an excellent model to characterize the underlying molecular and cellular mechanisms associated with immune – mediated demyelinating diseases.

III. IMMUNE RESPONSE DURING ACUTE DISEASE

Following intracranial infection, MHV replicates initially within the ependymal cells of the lateral ventricles before disseminating throughout the parenchyma, targeting astrocytes, oligodendrocytes, and microglia [38]. Neurons are spared within immunocompetent mice inoculated with neuroattenuated strains of MHV [49–51]. In contrast, neurovirulent strains such as MHV-JHM and MHV-4, are able to infect and replicate in both neurons and glia [52]. Following infection, MHV also traffics to the spinal cord, spreading through the cerebral spinal fluid and similarly infecting the local ependyma before disseminating throughout the parenchyma [38]. MHV infection of the CNS manifests significant early upregulation of inflammatory cytokines, chemokines, and matrix-metalloproteinases, all of which serve to initiate, attract, and support a robust host anti-viral response [40–42,53–58]. Neutrophils, macrophages, and NK cells are the primary innate immune cells recruited into the CNS immediately following MHV infection [59,60]. An overview of immune cell trafficking into the CNS in response to MHV infection is provided in Figure (1A). Neutrophils presumably respond to chemotactic signals through chemokine receptors, such as CXCR2, and infiltrate into the CNS (Hosking and Lane, unpublished observations), permeabilizing the blood brain barrier (BBB) through the secretion of matrix metalloproteinases (MMPs) that facilitate extracellular matrix and basement lamina degradation and subsequent leukocyte migration [61,62]. Neutrophils secrete MMP-9 [57,62], while MMP-3 and MMP-12 are derived from resident glia [56]. Little is known about the role that macrophages or NK cells play during acute MHV infection, as they appear to be dispensable [60,63].

Early following MHV infection, virus – specific T cells are detectable within the local lymph nodes and spleen and subsequently migrate into the CNS [64] Fig. (1A). Protective immunity and anti-viral responses generally conform to a T_H1 phenotype, characterized by vigorous IFN- γ secretion and cytolytic activity [43,44,65]. Virus specific T cell generation is not dependent upon either IL-12 or 23, as antibody neutralization of either p19 or p40 does not delay viral clearance [66]. Virus specific CD8⁺ T cells, the main cytolytic effector cell within the CNS, begin to accumulate by five days post infection [45,64], and are essential to controlling MHV replication [65,67]. CD8⁺ T cell infiltration into the CNS is concomitant with viral clearance from resident glia [65,68,69], and CD8⁺ T cells isolated from the CNS are directly cytolytic *ex vivo* [69,70], secreting IFN- γ and lytic molecules, including granzyme B and perforin [46]. *In vivo*, IFN- γ secretion controls viral replication within oligodendroglia [44,71], while perforin – mediated cytotoxicity eliminates MHV from astrocytes and microglia [43]. Recent evidence has also demonstrated that NKG2D signaling enhances CD8⁺ cytotoxic activity following MHV infection of the CNS [70]. Virus specific CD4⁺ T cells, which function mainly in a supporting role for CD8⁺ T cells, are also essential to controlling MHV viral replication [67,72]. *In vivo* CD4⁺ T cells secrete IFN- γ , facilitating viral clearance from oligodendroglia [44,71] and upregulating MHC class II expression on microglia, thus enhancing immune cell activity within the CNS [65,73]. CD8⁺ CTL activity and survival within the CNS is heavily dependent upon the presence of CD4⁺ T cells [74,75]. The mechanism(s) by which CD4⁺ T cells support and enhance CD8⁺ T cell activity is unresolved, however it is presumed to be a secreted factor, since CD4⁺ T cells are restricted to the vasculature during acute disease, instead of migrating throughout the parenchyma, possibly as a result of CD4⁺ T cell TIMP-1 expression [56]. Additionally, CD4⁺ T cells serve to exacerbate CNS inflammation, and later demyelination, by attracting macrophages through CCL5 secretion [67]. Antibody – secreting cells are detectable within the CNS of MHV infected mice by 5 days post infection and neutralizing antibody is detectable within the serum by 10 days post infection [76]. However, B cells do not participate in viral clearance during acute infection [77,78], rather MHV – specific antibodies prevent viral recrudescence in persistently infected mice [77–79] Fig. (1A).

IV. DEMYELINATION ASSOCIATED WITH MHV PERSISTENCE

Approximately two weeks after MHV infection viral loads are reduced to below detectable levels by plaque assay. Clearance is however incomplete, and virus persists primarily within oligodendrocytes; both viral antigen and RNA are detectable long after infection [40,80]. Mechanisms of viral persistence during chronic infection do not appear to include viral escape; although quasispecies of MHV are observed with genetic mutations [80], the observed mutations are random and do not facilitate escape from CD4+ or CD8+ surveillance, nor do they reflect specific immune pressure [81]. Mice surviving the initial infection develop an immune – mediated demyelinating disease. Symptomatic mice first demonstrate signs of ascending demyelination during acute infection that range from limp tails to partial and complete hind limb paralysis. Analysis of the spinal cords of chronically – infected mice confirms that the loss of myelin integrity is associated with the continued presence of both viral antigen and inflammatory immune cells [52] and not the apoptotic or necrotic death of myelinating oligodendrocytes [82]. Additionally, no role for complement or antibody – mediated demyelination has been established [83], although exogenous auto-antibodies can exacerbate demyelination independent of complement during chronic infection [84]. Nevertheless, the immunopathology observed during chronic MHV infection resembles what is observed in the majority of active MS lesions [39,85], making chronic MHV infection an excellent model to study mechanisms of pathogenesis and potential treatments. An overview of the relationship between viral replication, persistence, and demyelination is provided in Fig. (1B).

Within two weeks post – infection, immune infiltration into the CNS wanes, yet virus – specific T cells and macrophages continue to persist within the CNS for up to three months after infection [45–48]. Unlike with other models of CNS demyelination [86–88] and in MS [89–91], the emergence of autoreactive T cells to myelin epitopes that contribute to demyelination has not been observed during chronic MHV infection, indicating that T cell mediated anti-viral responses drive disease. Over time, CD8+ cytolytic activity is muted, presumably as a result of decreasing viral antigen [46,69], however these cells still retain their capacity to secrete IFN- γ [68].

The main effectors of demyelination during chronic MHV infection are T cells and macrophages. Demyelination is dramatically reduced in chronically infected mice that lack either CD4+ and/or CD8+ T cells [67,82], or are deficient in macrophage trafficking [67,92, 93], regardless of their ability to clear virus. Although the absence of CD8+ T cells in MHV infected mice does not influence demyelination [67], IFN- γ dependent demyelination was observed in *RAG-1* deficient recipients of CD8+ T cells [72,94,95], providing evidence CD8 + T cells are indeed capable of initiating and potentiating demyelination. As with other demyelinating diseases [96,97], ultrastructural analysis of MHV induced demyelinating lesions reveal macrophages stripping and engulfing myelin [98]. Additionally, deficiencies in macrophage trafficking abrogate demyelination [67,92,93], indicating that macrophages are also important mediators of demyelination Fig. (2).

Although the main effectors of demyelination appear to be T cells and macrophages, this does not discount the possibility that MHV plays a role in damage, especially since oligodendrocytes are the main reservoir of MHV during chronic infection [71,99]. In some MS lesions, oligodendrocyte apoptosis has also been observed [100,101], however the exact role of apoptosis in MS pathogenesis and pathology is unresolved [102]. Recent *in vitro* experiments with cultured murine oligodendrocytes has revealed that MHV is capable of directly inducing caspase dependent apoptosis through FAS – spike glycoprotein interactions [103–106]. However, *in vivo* oligodendrocyte apoptosis is not readily observed, nor has apoptosis been implicated to play any role in demyelination during chronic MHV infection [82]. Therefore,

it is likely that protective mechanisms exist *in vivo* to protect oligodendrocytes from MHV – induced apoptosis.

V. THERAPEUTIC APPROACHES FOR LIMITING DEMYELINATION AND PROMOTING REPAIR

As MHV – induced demyelination bears a number of similarities to the human – demyelinating disease MS, it offers an opportunity to examine underlying mechanisms and therapies that can have a direct application to disease amelioration and recovery. Mechanisms explored to date in chronic MHV infections have sought to address both the cause and effect of the immune – mediated demyelination. Specifically, efforts have focused upon limiting inflammatory cell infiltration into the CNS and enhancing the endogenous repair mechanisms through the surgical engraftment of exogenous myelinating cells.

T lymphocytes and macrophages are potent effectors of MHV – induced demyelination [67, 72,82] and actively participate in lesion formation of MS patients [7]. As a result, efforts have been taken to abrogate inflammation in an attempt to limit ongoing demyelination and allow for endogenous repair mechanisms to promote remyelination. We have focused specifically upon the chemotactic signals that govern T cell and macrophage infiltration into the CNS. Antibody – mediated neutralization of the T cell chemoattractant chemokine CXCL10, which is prominently expressed during chronic MHV infection and MS [40,107], specifically prevents CD4+ T cell accumulation within the CNS. The reduction in CD4+ T cell retention further abrogates CCL5 – directed accumulation of macrophages [67] and subsequently results in a drastic improvement in disease severity and accelerated remyelination [48]. Similar beneficial results were also observed following the antibody targeting of CXCR3, the receptor for CXCL10 [108] or in CXCL10 – deficient mice [109]. In other models of viral demyelination, such as Theilers murine encephalomyelitis virus (TMEV), antibody neutralization of CXCL10, which is also prominently expressed during chronic TMEV – mediated demyelination [110, 111], did not ameliorate inflammation or demyelination [112]. Instead, CXCL10 neutralization was associated with increased splenocyte TMEV – specific and auto-antigen lymphoproliferation [112]. Surprisingly, CXCL10 was not required during acute TMEV infection [112], whereas CXCL10 is protective and necessary during acute primary CNS infections with MHV [109,113], West Nile Virus [114,115], herpes virus simplex virus type 2 [116], and dengue virus [117].

In the neuroinflammatory demyelinating disease model experimental autoimmune encephalitis (EAE), the role for CXCL10 is unclear. CXCL10 is expressed in the CNS during EAE [118, 119], and antibody neutralization of CXCL10 using the adoptive transfer EAE model reduced disease incidence, severity, and the accumulation of PLP – reactive CD4+ in the CNS without affecting peripheral antigen – driven T cell responses [119]. However, recent studies have demonstrated that neutralization or genetic deletion of either CXCL10 or CXCR3 during active EAE increases disease severity [120–123]. Specifically, the absence of CXCL10 or CXCR3 enhanced peripheral antigen – driven T cell responses [121,123], reduced regulatory T cell infiltration into the CNS, and increased demyelination and axonal damage [122].

The diverse and contradictory roles for CXCL10 in viral and non-viral models of demyelination point to divergent underlying mechanisms of pathogenesis. Although viral antigen and RNA in oligodendrocytes clearly drive MHV – induced demyelination [40,44,68,71,80], infectious virus remains undetectable, and immune responses observed during chronic infection are solely directed against MHV and not against self antigens. During TMEV – induced demyelination, on the other hand, infectious virus is detectable in microglia and macrophages [124,125], and chronic inflammation is significantly enhanced by myelin-specific T cells elicited via epitope spreading during the course of chronic disease [86–88]. The paradoxical results observed in

EAE may be explained, in part, by the differing methods for the generation of encephalitogenic T cells (i.e. adoptive vs. active EAE) and the role for peripheral CXCL10 in generating an immune response. For example, in viral infections such as MHV, CXCL10 is not required for the *in vivo* generation or effector function of antigen – specific T cells [126], whereas CXCL10 is required for adjuvant – mediated T cell generation and effector function and contact hypersensitivity reactions [109].

Under various experimental conditions of demyelination, the CNS is capable of undergoing repair and remyelination [127–132]. However, repeated demyelinating episodes exhaust the ability of the CNS to adequately repair itself [133]. In rodent models of demyelination, oligodendrocyte progenitor cell (OPC) recruitment is limited to the area around a lesion, and long distance recruitment does not occur [134,135], indicating that any endogenous repair following demyelination must be local. Additionally, increased age negatively influences the capability OPCs to migrate, repopulate, and repair regions of damage in rodent models of demyelination [136–139]. MS is an adult disease that lasts decades [2], therefore, one must consider that adult OPCs have a reduced capacity to respond to the repeated demyelinating episodes that characterize MS. Recurrent demyelination and the subsequent exhaustion of the remyelinating progenitor pool within the CNS have been suggested to contribute to the development of chronic plaques and later secondary progressive MS [140]. Therefore, it is important to explore mechanisms and/or techniques that can aid the failed or restricted endogenous remyelination with the application of exogenous cells capable of inducing repair. *In vitro*, rodent stem cells and neural precursor cells (NPC) can be readily generated, expanded, and differentiated into oligodendrocyte – lineage cells [141–143]. In diverse experimental models of demyelination, transplanted NPCs robustly migrate and differentiate into oligodendrocytes *in vivo*, accelerating axon remyelination, and aiding in functional recovery [141,144–150].

Recent reports have detailed the divergent effects of inflammation upon NPCs. Since it is likely that NPC implantation for MS patients will occur within the context of an ongoing inflammatory environment, it is important that NPC survival, migration, and remyelinating capacity be assessed under a variety of *in vitro* and *in vivo* inflammatory conditions. *In vitro* cytokine stimulation of rodent NPCs with IFN- γ and/or TNF- α enhances migration and promotes MMP-2 and MMP-9 expression [151,152]. In EAE, transplanted NPCs specifically migrated toward inflamed white matter, while avoiding adjacent non-inflamed tissue [153]. In addition, NPCs transplanted into inflamed tissue infiltrated significantly farther than NPCs transplanted into un-inflamed CNS [153], indicating that inflammatory signals both direct and enhance the migration of NPCs *in vivo*. Indeed, conditioned media from microglia cultures enhances NPC transwell migration *in vitro* [154]. In ischemic rats, the chemokine CXCL12 mediates NPC migration to regions of damage [155,156]. Inflammatory stimuli are also necessary to cue remyelination following X-ray radiation – induced demyelination; in the absence of inflammation, transplanted NPCs migrated throughout the damaged tissue, but are incapable of differentiating into myelinating oligodendrocytes. However, with the initiation of a focal inflammatory response, NPCs successfully differentiated and myelinated the surrounding area [157]. Moreover, inflammation has also been observed beneficial following NPC transplant in a model of rat retinal myelination [158].

Conversely, recent reports have also described the negative effects of inflammatory cytokine stimuli upon NPCs. *In vitro* cytokine treatment increases NPC apoptosis and reduces FGF – stimulated proliferation [151]. NPCs treated with TNF- α robustly secrete the T cell and macrophage chemokines CXCL10 and CCL2 [159]. Moreover, cytokine treatment has also been reported to enhance NPC expression of the T cell co-stimulatory molecules CD80 and CD86 and functionally activates T cells proliferation *in vitro* [160]. Additionally, cross – linking CD80 with antibodies significantly enhances NPC induced apoptosis [160]. Therefore

it is plausible to construct a scenario in which implanted NPCs, which are subjected to inflammatory cytokine stimulation, respond with the T cell and macrophage chemoattractants CXCL10 and CCL2, mediating their own cytolysis or apoptosis. The *in vivo* reality is however much more complex. NPCs transplanted into inflamed chronic MHV infected spinal cords initiated remyelination, locomotor improvement, and axonal sparing [149]. Also, extensive remyelination has been observed in active MS lesions, concurrent with pathological damage [161], however the heterogeneity of MS lesions [4,5] make dissecting the relationship between inflammation and remyelination difficult. Finally, it is important that NPC transplantation itself does not exacerbate demyelination or inflammation. Transplantation of NPCs did not alter inflammation during chronic MHV infection [150], indicating that remyelination can occur in spite of on – going demyelination, without influencing immune cell trafficking. Additionally, in EAE, NPCs have even been deemed immunomodulatory, capable of attenuating inflammatory cell infiltration and disease severity [144,162–164]. Although the exact mechanism is unresolved, NPCs are capable of preventing peptide directed, concanavalin A, and IL-2 mediated proliferation of T cells *in vitro* regardless of mouse strain, suggesting a non-specific method of suppression [163]. Taken together these data demonstrate that transplantation of exogenous myelinating cells represent a promising treatment strategy for human demyelinating diseases, although the exact role in inflammation in either potentiating or impeding productive remyelination by endogenous and exogenous cells *in vivo* remains unresolved. It is likely that NPC transplants will form an arm of a multi – pronged approach that will be combined with anti – inflammatory treatments to treat both the effectors and the consequences of chronic demyelination in MS patients.

VI. PERSPECTIVES

This review highlights MHV as a model system for understanding viral – induced encephalomyelitis, specifically, the underlying mechanisms that dictate host defense, demyelination, and repair within the CNS. Although the exact causes of MS are unresolved and are likely due to multiple environmental and genetic factors, the immune – mediated demyelination observed during chronic MHV infection closely parallels the damage observed in patients after they develop MS, thus offering a platform to evaluate various treatment strategies that have the potential to offer relief and recovery. Promising treatment strategies explored during chronic MHV disease have included chemokine neutralization and NPC surgical transplantation, both of which have lead to functional recovery of treated animals. Recent discrepancies between EAE and MS, including the roles of TNF- α [165], IFN- γ [166], and IL-12/23 [167], where protective treatment strategies in EAE exacerbate or have no effect on MS patients during clinical trials, highlight the need for broader use of animal models that may offer different perspectives on MS and complement studies in EAE, including MHV and TMEV. As was previously indicated, the

Acknowledgments

This work was supported by National Multiple Sclerosis Society grant 3278 and National Institutes of Health grants NS41249 to T.E.L. M.P.H. was supported by NIH T32 AI-060573.

References

1. Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. *Ann Neurol* 1992;31:333–6. [PubMed: 1637140]
2. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? *Neurology* 2007;68:326–37. [PubMed: 17261678]
3. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. *Neurology* 2008;71:129–35. [PubMed: 18606967]

4. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. *Trends Mol Med* 2001;7:115–21. [PubMed: 11286782]
5. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. *Ann Neurol* 2000;47:707–17. [PubMed: 10852536]
6. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. *Nat Immunol* 2007;8:913–9. [PubMed: 17712344]
7. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. *N Engl J Med* 2000;343:938–52. [PubMed: 11006371]
8. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. *Ann Neurol* 2007;61:288–99. [PubMed: 17444504]
9. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. *Ann Neurol* 2007;61:504–13. [PubMed: 17492755]
10. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. *N Engl J Med* 2007;357:851–62. [PubMed: 17660530]
11. Lincoln MR, Montpetit A, Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. *Nat Genet* 2005;37:1108–12. [PubMed: 16186814]
12. Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. *Brain* 2002;125:952–60. [PubMed: 11960885]
13. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. *Ann Neurol* 1994;36 (Suppl):S25–8. [PubMed: 8017885]
14. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. *Ann Neurol* 2006;59:499–503. [PubMed: 16502434]
15. Sotelo J, Martinez-Palomo A, Ordonez G, Pineda B. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis. *Ann Neurol* 2008;63:303–11. [PubMed: 18306233]
16. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. *Lancet* 1971;1:1257–60. [PubMed: 4104715]
17. Hou J, Major EO. Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host. *J Neurovirol* 2000;6(Suppl 2):S98–S100. [PubMed: 10871795]
18. Griffin, DE.; Bellini, WJ. Measles Virus. Philadelphia: Lippincott-Raven Publishers; 1996. *Fields Virology*; p. 1267-96.
19. Hahn AF. Guillain-Barre syndrome. *Lancet* 1998;352:635–41. [PubMed: 9746040]
20. Holmes, K.; Lai, M. Coronaviridae: The Viruses and Their Replication. Philadelphia: Lippincott-Raven Publishers; 1996. *Fields Virology*; p. 1075-94.
21. McIntosh, K. Coronaviruses. Philadelphia: Lippincott-Raven Publishers; 1996. *Fields Virology*; p. 1095-104.
22. Cheever FS, Daniels JB, Pappenheimer AM, Bailey OT. A murine virus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin. *Journal of Experimental Medicine* 1949;90:181–210. [PubMed: 18137294]
23. Perlman, SR.; Lane, TE.; Buchmeier, MJ. Coronaviruses: Hepatitis, peritonitis, and central nervous system disease. Philadelphia: Lippincott Williams & Wilkins; 1999. *Effects of Microbes on the Immune System*; p. 331-48.
24. Compton SR, Stephensen CB, Snyder SW, Weismiller DG, Holmes KV. Coronavirus species specificity: murine coronavirus binds to a mouse-specific epitope on its carcinoembryonic antigen-related receptor glycoprotein. *J Virol* 1992;66:7420–8. [PubMed: 1279203]
25. Williams RK, Jiang GS, Snyder SW, Frana MF, Holmes KV. Purification of the 110-kilodalton glycoprotein receptor for mouse hepatitis virus (MHV)-A59 from mouse liver and identification of a nonfunctional, homologous protein in MHV-resistant SJL/J mice. *J Virol* 1990;64:3817–23. [PubMed: 2164599]

26. Ontiveros E, Kim TS, Gallagher TM, Perlman S. Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein. *J Virol* 2003;77:10260–9. [PubMed: 12970410]
27. Iacono KT, Kazi L, Weiss SR. Both spike and background genes contribute to murine coronavirus neurovirulence. *J Virol* 2006;80:6834–43. [PubMed: 16809289]
28. Phillips JJ, Chua MM, Rall GF, Weiss SR. Murine coronavirus spike glycoprotein mediates degree of viral spread, inflammation, and virus-induced immunopathology in the central nervous system. *Virology* 2002;301:109–20. [PubMed: 12359451]
29. Hemmila E, Turbide C, Olson M, Jothy S, Holmes KV, Beauchemin N. Ceacam1a^{-/-} mice are completely resistant to infection by murine coronavirus mouse hepatitis virus A59. *J Virol* 2004;78:10156–65. [PubMed: 15331748]
30. Nakagaki K, Nakagaki K, Taguchi F. Receptor-independent spread of a highly neurotropic murine coronavirus JHMV strain from initially infected microglial cells in mixed neural cultures. *J Virol* 2005;79:6102–10. [PubMed: 15857995]
31. Thorp EB, Gallagher TM. Requirements for CEACAMs and cholesterol during murine coronavirus cell entry. *J Virol* 2004;78:2682–92. [PubMed: 14990688]
32. Miura TA, Travanty EA, Oko L, et al. The spike glycoprotein of murine coronavirus MHV-JHM mediates receptor-independent infection and spread in the central nervous systems of Ceacam1a^{-/-} Mice. *J Virol* 2008;82:755–63. [PubMed: 18003729]
33. Chen DS, Asanaka M, Yokomori K, et al. A pregnancy-specific glycoprotein is expressed in the brain and serves as a receptor for mouse hepatitis virus. *Proc Natl Acad Sci U S A* 1995;92:12095–9. [PubMed: 8618851]
34. Gallagher TM, Buchmeier MJ, Perlman S. Cell receptor-independent infection by a neurotropic murine coronavirus. *Virology* 1992;191:517–22. [PubMed: 1413526]
35. Godfraind C, Langreth SG, Cardellicchio CB, et al. Tissue and cellular distribution of an adhesion molecule in the carcinoembryonic antigen family that serves as a receptor for mouse hepatitis virus. *Lab Invest* 1995;73:615–27. [PubMed: 7474935]
36. Godfraind C, Havaux N, Holmes KV, Coutelier JP. Role of virus receptor-bearing endothelial cells of the blood-brain barrier in preventing the spread of mouse hepatitis virus-A59 into the central nervous system. *J Neurovirol* 1997;3:428–34. [PubMed: 9475114]
37. Ramakrishna C, Bergmann CC, Holmes KV, Stohlman SA. Expression of the mouse hepatitis virus receptor by central nervous system microglia. *J Virol* 2004;78:7828–32. [PubMed: 15220458]
38. Wang FI, Hinton DR, Gilmore W, Trousdale MD, Fleming JO. Sequential infection of glial cells by the murine hepatitis virus JHM strain (MHV-4) leads to a characteristic distribution of demyelination. *Lab Invest* 1992;66:744–54. [PubMed: 1318460]
39. Houtman JJ, Fleming JO. Pathogenesis of mouse hepatitis virus-induced demyelination. *J Neurovirol* 1996;2:361–76. [PubMed: 8972418]
40. Lane TE V, Asensio C, Yu N, Paoletti AD, Campbell IL, Buchmeier MJ. Dynamic regulation of alpha- and beta-chemokine expression in the central nervous system during mouse hepatitis virus-induced demyelinating disease. *J Immunol* 1998;160:970–8. [PubMed: 9551936]
41. Pearce BD, Hobbs MV, McGraw TS, Buchmeier MJ. Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo. *J Virol* 1994;68:5483–95. [PubMed: 8057431]
42. Parra B, Hinton DR, Lin MT, Cua DJ, Stohlman SA. Kinetics of cytokine mRNA expression in the central nervous system following lethal and nonlethal coronavirus-induced acute encephalomyelitis. *Virology* 1997;233:260–70. [PubMed: 9217050]
43. Lin MT, Stohlman SA, Hinton DR. Mouse hepatitis virus is cleared from the central nervous systems of mice lacking perforin-mediated cytotoxicity. *J Virol* 1997;71:383–91. [PubMed: 8985361]
44. Parra B, Hinton DR, Marten NW, et al. IFN-gamma is required for viral clearance from central nervous system oligodendroglia. *J Immunol* 1999;162:1641–7. [PubMed: 9973424]
45. Marten NW, Stohlman SA, Bergmann CC. Role of viral persistence in retaining CD8(+) T cells within the central nervous system. *J Virol* 2000;74:7903–10. [PubMed: 10933698]

46. Ramakrishna C, Stohlman SA, Atkinson RA, Hinton DR, Bergmann CC. Differential regulation of primary and secondary CD8+ T cells in the central nervous system. *J Immunol* 2004;173:6265–73. [PubMed: 15528365]
47. Castro RF, Evans GD, Jaszewski A, Perlman S. Coronavirus-induced demyelination occurs in the presence of virus-specific cytotoxic T cells. *Virology* 1994;200:733–43. [PubMed: 8178457]
48. Liu MT, Keirstead HS, Lane TE. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. *J Immunol* 2001;167:4091–7. [PubMed: 11564831]
49. Buchmeier MJ, Lewicki HA, Talbot PJ, Knobler RL. Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody. *Virology* 1984;132:261–70. [PubMed: 6199889]
50. Fleming JO, Stohlman SA, Harmon RC, Lai MM, Frelinger JA, Weiner LP. Antigenic relationships of murine coronaviruses: analysis using monoclonal antibodies to JHM (MHV-4) virus. *Virology* 1983;131:296–307. [PubMed: 6318433]
51. Ireland DD, Stohlman SA, Hinton DR, Atkinson R, Bergmann CC. Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells. *J Virol* 2008;82:300–10. [PubMed: 17928334]
52. Stohlman SA, Hinton David R. Viral Induced Demyelination. *Brain Pathology* 2001;11:92–106. [PubMed: 11145206]
53. Rempel JD, Quina LA, Blakely-Gonzales PK, Buchmeier MJ, Gruol DL. Viral induction of central nervous system innate immune responses. *J Virol* 2005;79:4369–81. [PubMed: 15767437]
54. Rempel JD, Murray SJ, Meisner J, Buchmeier MJ. Differential regulation of innate and adaptive immune responses in viral encephalitis. *Virology* 2004;318:381–92. [PubMed: 14972563]
55. Sun N, Grzybicki D, Castro RF, Murphy S, Perlman S. Activation of astrocytes in the spinal cord of mice chronically infected with a neurotropic coronavirus. *Virology* 1995;213:482–93. [PubMed: 7491773]
56. Zhou J, Marten NW, Bergmann CC, Macklin WB, Hinton DR, Stohlman SA. Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis. *J Virol* 2005;79:4764–73. [PubMed: 15795262]
57. Zhou J, Stohlman SA, Atkinson R, Hinton DR, Marten NW. Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection. *J Virol* 2002;76:7374–84. [PubMed: 12097550]
58. Glass WG, Chen BP, Liu MT, Lane TE. Mouse hepatitis virus infection of the central nervous system: chemokine-mediated regulation of host defense and disease. *Viral Immunol* 2002;15:261–72. [PubMed: 12081011]
59. Templeton SP, Kim TS, O'Malley K, Perlman S. Maturation and localization of macrophages and microglia during infection with a neurotropic murine coronavirus. *Brain Pathol* 2008;18:40–51. [PubMed: 17935605]
60. Zuo J, Stohlman SA, Hoskin JB, Hinton DR, Atkinson R, Bergmann CC. Mouse hepatitis virus pathogenesis in the central nervous system is independent of IL-15 and natural killer cells. *Virology* 2006;350:206–15. [PubMed: 16510164]
61. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. *Nat Rev Neurosci* 2001;2:502–11. [PubMed: 11433375]
62. Zhou J, Stohlman SA, Hinton DR, Marten NW. Neutrophils promote mononuclear cell infiltration during viral-induced encephalitis. *J Immunol* 2003;170:3331–6. [PubMed: 12626593]
63. Xue S, Sun N, Van Rooijen N, Perlman S. Depletion of blood-borne macrophages does not reduce demyelination in mice infected with a neurotropic coronavirus. *J Virol* 1999;73:6327–34. [PubMed: 10400724]
64. Marten NW, Stohlman SA, Zhou J, Bergmann CC. Kinetics of virus-specific CD8+-T-cell expansion and trafficking following central nervous system infection. *J Virol* 2003;77:2775–8. [PubMed: 12552021]
65. Bergmann CC, Parra B, Hinton DR, Chandran R, Morrison M, Stohlman SA. Perforin-mediated effector function within the central nervous system requires IFN-gamma-mediated MHC up-regulation. *J Immunol* 2003;170:3204–13. [PubMed: 12626579]

66. Held KS, Glass WG, Orlovsky YI, et al. Generation of a Protective T-Cell Response Following Coronavirus Infection of the Central Nervous System Is Not Dependent on IL-12/23 Signaling. *Viral Immunol* 2008;21:173–88. [PubMed: 18570589]
67. Lane TE, Liu MT, Chen BP, et al. A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. *J Virol* 2000;74:1415–24. [PubMed: 10627552]
68. Bergmann CC, Lane TE, Stohlman SA. Coronavirus infection of the central nervous system: host-virus stand-off. *Nat Rev Microbiol* 2006;4:121–32. [PubMed: 16415928]
69. Bergmann CC, Altman JD, Hinton D, Stohlman SA. Inverted immunodominance and impaired cytolytic function of CD8+ T cells during viral persistence in the central nervous system. *J Immunol* 1999;163:3379–87. [PubMed: 10477608]
70. Walsh KB, Lanier LL, Lane TE. NKG2D receptor signaling enhances cytolytic activity by virus-specific CD8+ T cells: evidence for a protective role in virus-induced encephalitis. *J Virol* 2008;82:3031–44. [PubMed: 18160433]
71. Gonzalez JM, Bergmann CC, Ramakrishna C, et al. Inhibition of interferon-gamma signaling in oligodendroglia delays coronavirus clearance without altering demyelination. *Am J Pathol* 2006;168:796–804. [PubMed: 16507895]
72. Wu GF, Dandekar AA, Pewe L, Perlman S. CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. *J Immunol* 2000;165:2278–86. [PubMed: 10925317]
73. Bergmann CC, Parra B, Hinton DR, Ramakrishna C, Dowdell KC, Stohlman SA. Perforin and gamma interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells. *J Virol* 2004;78:1739–50. [PubMed: 14747539]
74. Stohlman SA, Bergmann CC, Lin MT, Cua DJ, Hinton DR. CTL effector function within the central nervous system requires CD4+ T cells. *J Immunol* 1998;160:2896–904. [PubMed: 9510193]
75. Zhou J, Hinton DR, Stohlman SA, Liu CP, Zhong L, Marten NW. Maintenance of CD8+ T cells during acute viral infection of the central nervous system requires CD4+ T cells but not interleukin-2. *Viral Immunol* 2005;18:162–9. [PubMed: 15802960]
76. Tschen SI, Bergmann CC, Ramakrishna C, Morales S, Atkinson R, Stohlman SA. Recruitment kinetics and composition of antibody-secreting cells within the central nervous system following viral encephalomyelitis. *J Immunol* 2002;168:2922–9. [PubMed: 11884463]
77. Ramakrishna C, Bergmann CC, Atkinson R, Stohlman SA. Control of central nervous system viral persistence by neutralizing antibody. *J Virol* 2003;77:4670–8. [PubMed: 12663773]
78. Ramakrishna C, Stohlman SA, Atkinson RD, Shlomchik MJ, Bergmann CC. Mechanisms of central nervous system viral persistence: the critical role of antibody and B cells. *J Immunol* 2002;168:1204–11. [PubMed: 11801656]
79. Lin MT, Hinton DR, Marten NW, Bergmann CC, Stohlman SA. Antibody prevents virus reactivation within the central nervous system. *J Immunol* 1999;162:7358–68. [PubMed: 10358187]
80. Adami C, Pooley J, Glomb J, et al. Evolution of mouse hepatitis virus (MHV) during chronic infection: quasispecies nature of the persisting MHV RNA. *Virology* 1995;209:337–46. [PubMed: 7778268]
81. Bergmann C, Dimacali E, Stohl S, et al. Variability of persisting MHV RNA sequences constituting immune and replication-relevant domains. *Virology* 1998;244:563–72. [PubMed: 9601524]
82. Wu GF, Perlman S. Macrophage infiltration, but not apoptosis, is correlated with immune-mediated demyelination following murine infection with a neurotropic coronavirus. *J Virol* 1999;73:8771–80. [PubMed: 10482631]
83. Matthews AE, Lavi E, Weiss SR, Paterson Y. Neither B cells nor T cells are required for CNS demyelination in mice persistently infected with MHV-A59. *J Neurovirol* 2002;8:257–64. [PubMed: 12053280]
84. Burrer R, Buchmeier MJ, Wolfe T, et al. Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies. *Am J Pathol* 2007;170:557–66. [PubMed: 17255324]
85. Matthews AE, Weiss SR, Paterson Y. Murine hepatitis virus—a model for virus-induced CNS demyelination. *J Neurovirol* 2002;8:76–85. [PubMed: 11935460]
86. Miller SD, Vanderlugt CL, Begolka WS, et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. *Nat Med* 1997;3:1133–6. [PubMed: 9334726]

87. Katz-Levy Y, Neville KL, Padilla J, et al. Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APCs in Theiler's virus-infected mice. *J Immunol* 2000;165:5304–14. [PubMed: 11046065]
88. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. *Nat Med* 2005;11:335–9. [PubMed: 15735651]
89. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. *J Clin Invest* 1997;99:1682–90. [PubMed: 9120012]
90. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. *Brain* 2000;123(Pt 3):508–18. [PubMed: 10686174]
91. Tuohy VK, Yu M, Yin L, Kawczak JA, Kinkel RP. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. *J Exp Med* 1999;189:1033–42. [PubMed: 10190894]
92. Glass WG, Hickey MJ, Hardison JL, Liu MT, Manning JE, Lane TE. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. *J Immunol* 2004;172:4018–25. [PubMed: 15034013]
93. Glass WG, Liu MT, Kuziel WA, Lane TE. Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus. *Virology* 2001;288:8–17. [PubMed: 11543653]
94. Pewe L, Haring J, Perlman S. CD4 T-cell-mediated demyelination is increased in the absence of gamma interferon in mice infected with mouse hepatitis virus. *J Virol* 2002;76:7329–33. [PubMed: 12072531]
95. Pewe L, Perlman S. Cutting edge: CD8 T cell-mediated demyelination is IFN-gamma dependent in mice infected with a neurotropic coronavirus. *J Immunol* 2002;168:1547–51. [PubMed: 11823480]
96. Epstein LG, Prineas JW, Raine CS. Attachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis. *J Neurol Sci* 1983;61:341–8. [PubMed: 6655487]
97. Field EJ, Raine CS. Experimental allergic encephalomyelitis. An electron microscopic study. *Am J Pathol* 1966;49:537–53. [PubMed: 5920329]
98. Fleury HJ, Sheppard RD, Bornstein MB, Raine CS. Further ultrastructural observations of virus morphogenesis and myelin pathology in JHM virus encephalomyelitis. *Neuropathol Appl Neurobiol* 1980;6:165–79. [PubMed: 6250094]
99. Gonzalez JM, Bergmann CC, Fuss B, et al. Expression of a dominant negative IFN-gammareceptor on mouse oligodendrocytes. *Glia* 2005;51:22–34. [PubMed: 15779088]
100. Matute C, Perez-Cerda F. Multiple sclerosis: novel perspectives on newly forming lesions. *Trends Neurosci* 2005;28:173–5. [PubMed: 15808350]
101. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. *Ann Neurol* 2004;55:458–68. [PubMed: 15048884]
102. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. *N Engl J Med* 2006;354:942–55. [PubMed: 16510748]
103. Liu Y, Cai Y, Zhang X. Induction of caspase-dependent apoptosis in cultured rat oligodendrocytes by murine coronavirus is mediated during cell entry and does not require virus replication. *J Virol* 2003;77:11952–63. [PubMed: 14581532]
104. Liu Y, Pu Y, Zhang X. Role of the mitochondrial signaling pathway in murine coronavirus-induced oligodendrocyte apoptosis. *J Virol* 2006;80:395–403. [PubMed: 16352564]
105. Liu Y, Zhang X. Expression of cellular oncogene Bcl-xL prevents coronavirus-induced cell death and converts acute infection to persistent infection in progenitor rat oligodendrocytes. *J Virol* 2005;79:47–56. [PubMed: 15596800]
106. Liu Y, Zhang X. Murine coronavirus-induced oligodendrocyte apoptosis is mediated through the activation of the Fas signaling pathway. *Virology* 2007;360:364–75. [PubMed: 17156812]
107. Simpson JE, Newcombe J, Cuzner ML, Woodroffe MN. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. *Neuropathol Appl Neurobiol* 2000;26:133–42. [PubMed: 10840276]

108. Stiles LN, Hosking MP, Edwards RA, Strieter RM, Lane TE. Differential roles for CXCR3 in CD4⁺ and CD8⁺ T cell trafficking following viral infection of the CNS. *Eur J Immunol* 2006;36:613–22. [PubMed: 16479546]
109. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. *J Immunol* 2002;168:3195–204. [PubMed: 11907072]
110. Hoffman LM, Fife BT, Begolka WS, Miller SD, Karpus WJ. Central nervous system chemokine expression during Theiler's virus-induced demyelinating disease. *J Neurovirol* 1999;5:635–42. [PubMed: 10602404]
111. Theil DJ, Tsunoda I, Libbey JE, Derfuss TJ, Fujinami RS. Alterations in cytokine but not chemokine mRNA expression during three distinct Theiler's virus infections. *J Neuroimmunol* 2000;104:22–30. [PubMed: 10683511]
112. Tsunoda I, Lane TE, Blackett J, Fujinami RS. Distinct roles for IP-10/CXCL10 in three animal models, Theiler's virus infection, EAE, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10. *Mult Scler* 2004;10:26–34. [PubMed: 14760949]
113. Liu MT, Chen BP, Oertel P, et al. The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. *J Immunol* 2000;165:2327–30. [PubMed: 10946253]
114. Klein RS, Lin E, Zhang B, et al. Neuronal CXCL10 directs CD8⁺ T-cell recruitment and control of West Nile virus encephalitis. *J Virol* 2005;79:11457–66. [PubMed: 16103196]
115. Zhang B, Chan YK, Lu B, Diamond MS, Klein RS. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. *J Immunol* 2008;180:2641–9. [PubMed: 18250476]
116. Thapa M, Welner RS, Pelayo R, Carr DJ. CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. *J Immunol* 2008;180:1098–106. [PubMed: 18178850]
117. Hsieh MF, Lai SL, Chen JP, et al. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. *J Immunol* 2006;177:1855–63. [PubMed: 16849497]
118. Ransohoff RM, Hamilton TA, Tani M, et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. *FASEB J* 1993;7:592–600. [PubMed: 8472896]
119. Fife BT, Kennedy KJ, Paniagua MC, et al. CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4⁺ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. *J Immunol* 2001;166:7617–24. [PubMed: 11390519]
120. Narumi S, Kaburaki T, Yoneyama H, Iwamura H, Kobayashi Y, Matsushima K. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. *Eur J Immunol* 2002;32:1784–91. [PubMed: 12115662]
121. Liu L, Huang D, Matsui M, et al. Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3^{-/-} mice with experimental autoimmune encephalomyelitis. *J Immunol* 2006;176:4399–409. [PubMed: 16547278]
122. Muller M, Carter SL, Hofer MJ, et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. *J Immunol* 2007;179:2774–86. [PubMed: 17709491]
123. Klein RS, Izikson L, Means T, et al. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. *J Immunol* 2004;172:550–9. [PubMed: 14688366]
124. Trottier M, Schlitt BP, Kung AY, Lipton HL. Transition from acute to persistent Theiler's virus infection requires active viral replication that drives proinflammatory cytokine expression and chronic demyelinating disease. *J Virol* 2004;78:12480–8. [PubMed: 15507635]
125. Lipton HL, Twaddle G, Jelachich ML. The predominant virus antigen burden is present in macrophages in Theiler's murine encephalomyelitis virus-induced demyelinating disease. *J Virol* 1995;69:2525–33. [PubMed: 7884902]

126. Stiles LN, Hardison JL, Schaumburg CS, Whitman LM, Lane TE. T cell antiviral effector function is not dependent on CXCL10 following murine coronavirus infection. *J Immunol* 2006;177:8372–80. [PubMed: 17142734]
127. Albrecht PJ, Murtie JC, Ness JK, et al. Astrocytes produce CNTF during the remyelination phase of viral-induced spinal cord demyelination to stimulate FGF-2 production. *Neurobiol Dis* 2003;13:89–101. [PubMed: 12828933]
128. Messersmith DJ, Murtie JC, Le TQ, Frost EE, Armstrong RC. Fibroblast growth factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating disease with extensive remyelination. *J Neurosci Res* 2000;62:241–56. [PubMed: 11020217]
129. Hampton DW, Anderson J, Pryce G, et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. *J Neuroimmunol* 2008;201–202:200–11.
130. Snyder DH, Valsamis MP, Stone SH, Raine CS. Progressive demyelination and reparative phenomena in chronic experimental allergic encephalomyelitis. *J Neuropathol Exp Neurol* 1975;34:209–21. [PubMed: 1141960]
131. Zamvil S, Nelson P, Trotter J, et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. *Nature* 1985;317:355–8. [PubMed: 2413363]
132. Murray PD, McGavern DB, Sathornsumetee S, Rodriguez M. Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis. *Brain* 2001;124:1403–16. [PubMed: 11408335]
133. Chari DM, Blakemore WF. New insights into remyelination failure in multiple sclerosis: implications for glial cell transplantation. *Mult Scler* 2002;8:271–7. [PubMed: 12166495]
134. Franklin RJ, Blakemore WF. Transplanting oligodendrocyte progenitors into the adult CNS. *J Anat* 1997;190(Pt 1):23–33. [PubMed: 9034879]
135. Franklin RJ, Gilson JM, Blakemore WF. Local recruitment of remyelinating cells in the repair of demyelination in the central nervous system. *J Neurosci Res* 1997;50:337–44. [PubMed: 9373042]
136. Zhao C, Li WW, Franklin RJ. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. *Neurobiol Aging* 2006;27:1298–307. [PubMed: 16051398]
137. Blakemore WF, Irvine KA. Endogenous or exogenous oligodendrocytes for remyelination. *J Neurol Sci* 2008;265:43–6. [PubMed: 17826797]
138. Shen S, Sandoval J, Swiss VA, et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. *Nat Neurosci*. 2008
139. Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. *J Neurosci* 2002;22:2451–9. [PubMed: 11923409]
140. Franklin RJ. Why does remyelination fail in multiple sclerosis? *Nat Rev Neurosci* 2002;3:705–14. [PubMed: 12209119]
141. Liu S, Qu Y, Stewart TJ, et al. Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. *Proc Natl Acad Sci U S A* 2000;97:6126–31. [PubMed: 10823956]
142. Ben-Hur T, Rogister B, Murray K, Rougon G, Dubois-Dalcq M. Growth and fate of PSA-NCAM+ precursors of the postnatal brain. *J Neurosci* 1998;18:5777–88. [PubMed: 9671666]
143. Brustle O, Jones KN, Learish RD, et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. *Science* 1999;285:754–6. [PubMed: 10427001]
144. Einstein O, Karussis D, Grigoriadis N, et al. Intraventricular transplantation of neural precursor cell spheres attenuates acute experimental allergic encephalomyelitis. *Mol Cell Neurosci* 2003;24:1074–82. [PubMed: 14697670]
145. Pluchino S, Quattrini A, Brambilla E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. *Nature* 2003;422:688–94. [PubMed: 12700753]
146. Zhang J, Li Y, Chen J, et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. *Exp Neurol* 2005;195:16–26. [PubMed: 15904921]

147. Blakemore WF, Gilson JM, Crang AJ. Transplanted glial cells migrate over a greater distance and remyelinate demyelinated lesions more rapidly than endogenous remyelinating cells. *J Neurosci Res* 2000;61:288–94. [PubMed: 10900075]
148. Nistor GI, Totoiu MO, Haque N, Carpenter MK, Keirstead HS. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. *Glia* 2005;49:385–96. [PubMed: 15538751]
149. Totoiu MO, Nistor GI, Lane TE, Keirstead HS. Remyelination, axonal sparing, and locomotor recovery following transplantation of glial-committed progenitor cells into the MHV model of multiple sclerosis. *Exp Neurol* 2004;187:254–65. [PubMed: 15144852]
150. Hardison JL, Nistor G, Gonzalez R, Keirstead HS, Lane TE. Transplantation of glial-committed progenitor cells into a viral model of multiple sclerosis induces remyelination in the absence of an attenuated inflammatory response. *Exp Neurol* 2006;197:420–9. [PubMed: 16297915]
151. Ben-Hur T, Ben-Menachem O, Furer V, Einstein O, Mizrahi-Kol R, Grigoriadis N. Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. *Mol Cell Neurosci* 2003;24:623–31. [PubMed: 14664813]
152. Ben-Hur T, Ben-Yosef Y, Mizrahi-Kol R, Ben-Menachem O, Miller A. Cytokine-mediated modulation of MMPs and TIMPs in multipotential neural precursor cells. *J Neuroimmunol* 2006;175:12–8. [PubMed: 16580738]
153. Ben-Hur T, Einstein O, Mizrahi-Kol R, et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. *Glia* 2003;41:73–80. [PubMed: 12465047]
154. Aarum J, Sandberg K, Haerberlein SL, Persson MA. Migration and differentiation of neural precursor cells can be directed by microglia. *Proc Natl Acad Sci U S A* 2003;100:15983–8. [PubMed: 14668448]
155. Imitola J, Raddassi K, Park KI, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. *Proc Natl Acad Sci U S A* 2004;101:18117–22. [PubMed: 15608062]
156. Kelly S, Bliss TM, Shah AK, et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. *Proc Natl Acad Sci U S A* 2004;101:11839–44. [PubMed: 15280535]
157. Foote AK, Blakemore WF. Inflammation stimulates remyelination in areas of chronic demyelination. *Brain* 2005;128:528–39. [PubMed: 15699059]
158. Setzu A, Lathia JD, Zhao C, et al. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. *Glia* 2006;54:297–303. [PubMed: 16856149]
159. Sheng WS, Hu S, Ni HT, Rowen TN, Lokensgard JR, Peterson PK. TNF-alpha-induced chemokine production and apoptosis in human neural precursor cells. *J Leukoc Biol* 2005;78:1233–41. [PubMed: 16314440]
160. Imitola J, Comabella M, Chandraker AK, et al. Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. *Am J Pathol* 2004;164:1615–25. [PubMed: 15111308]
161. Bruck W, Kuhlmann T, Stadelmann C. Remyelination in multiple sclerosis. *J Neurol Sci* 2003;206:181–5. [PubMed: 12559508]
162. Aharonowiz M, Einstein O, Fainstein N, Lassmann H, Reubinoff B, Ben-Hur T. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. *PLoS ONE* 2008;3:e3145. [PubMed: 18773082]
163. Einstein O, Fainstein N, Vaknin I, et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. *Ann Neurol* 2007;61:209–18. [PubMed: 17187374]
164. Einstein O, Grigoriadis N, Mizrahi-Kol R, et al. Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. *Exp Neurol* 2006;198:275–84. [PubMed: 16472805]
165. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. *Neurology* 1996;47:1531–4. [PubMed: 8960740]

166. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. *Neurology* 1987;37:1097–102. [PubMed: 3110648]
167. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. *Lancet Neurol* 2008;7:796–804. [PubMed: 18703004]

Figure 1. Kinetics of viral replication and neuroinflammation following MHV infection of the CNS (A) Following intracranial infection of mice, MHV replicates initially within ependymal cells and later disseminates to astrocytes, oligodendrocytes, and microglia, quickly reaching peak load between 4–6 days post – infection [38,68]. Cells of the innate immune system *e.g.* neutrophils, NK cells, and macrophages are rapidly recruited to the CNS within the first few days following infection [59,60]. While neutrophils are important for permeabilizing the blood brain barrier, cellular components of the innate immune response are incapable of controlling viral replication. Beginning at 5 days post – infection, virus – specific T cells enter the CNS [45,64] and control viral replication through perforin-mediated cytotoxicity and IFN- γ secretion. By two weeks post-infection MHV is generally undetectable in the CNS by plaque assay,

however T cells and macrophages persist within the CNS [45–48]. Neutralizing antibody, while detectable during acute infection does not play any appreciable role in viral clearance; rather virus-specific antibody is responsible for preventing viral recrudescence during chronic infection [77–79]. **(B)** Even though replicating virus is undetectable in the CNS at later stages of infection, both viral antigen and/or RNA persist within the CNS for up to a year. Viral persistence is responsible for continued T cell and macrophage infiltration into the CNS that leads to chronic demyelination [40,80]. Data depicted in panels **A** and **B** are schematic curves representative of published results.

Figure 2. Demyelination in mice persistently infected with MHV

Following acute disease, MHV will persist primarily in astrocytes and oligodendrocytes. Activated astrocytes secrete the T cell and macrophage chemokines CXCL10 and CCL5, serving to attract CD4⁺ T cells, CD8⁺ T cells, and macrophages to migrate across the blood brain barrier and into the perivascular space. CD4⁺ T cells are also capable of secreting CCL5, further enhancing macrophage accumulation. Both CD4⁺ and CD8⁺ T cells secrete IFN-γ, activating macrophages and aiding in viral clearance from persistently infected oligodendrocytes. Activated macrophages in turn digest myelin debris and enhance the immune-mediated demyelination. Targeted neutralization of either CXCL10 [48] or CCL5 [92] prevents the accumulation of CD4⁺ T cells or macrophages, respectively, muting chronic

inflammation within the CNS and allowing remyelination to occur. Engrafted neural precursor cells also enhance remyelination, presumably by directly myelinating axons [149,150].